Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

41%

7 of 17 completed with results

Key Signals

7 with results100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (2)
P 1 (7)
P 2 (2)

Trial Status

Completed17
Unknown2
Enrolling By Invitation1
Not Yet Recruiting1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT06805487Phase 1CompletedPrimary

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT04917861Phase 2CompletedPrimary

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT03611946Phase 1CompletedPrimary

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

NCT04398901Enrolling By InvitationPrimary

Neurodevelopmental Outcomes in ZIKV-Exposed Children

NCT05123222Phase 1CompletedPrimary

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

NCT06859619Not ApplicableNot Yet Recruiting

Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases

NCT04182685CompletedPrimary

Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua

NCT04064905Phase 1CompletedPrimary

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

NCT03014089Phase 1CompletedPrimary

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

NCT03110770Phase 2CompletedPrimary

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT01099852Unknown

Cohort of Patients Infected by an Arbovirus

NCT02996890Phase 1CompletedPrimary

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

NCT03188731CompletedPrimary

ZIKAlliance Pregnant Women Cohort

NCT03204409WithdrawnPrimary

ZIKAlliance Natural History Study

NCT03393286CompletedPrimary

ZIKAlliance Children Cohort (ZIKAllianceCH)

NCT03263195Completed

Prospective Cohort Study of HIV and Zika in Infants and Pregnancy

NCT03106714CompletedPrimary

Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil

NCT02733796CompletedPrimary

Persistence of Zika Virus in Semen After Acute Infection

NCT03425149Phase 1CompletedPrimary

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

NCT02794181CompletedPrimary

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

Scroll to load more

Research Network

Activity Timeline